Sylvia Cohen-Kaminsky is Director of Research at the French National Center for Scientific Research (CNRS) and Vice-Chair of the Scientific Council of the Paris Saclay Faculty of Medicine. She works in the Inserm UMR_S999 unit, which is dedicated to « Pulmonary Arterial Hypertension: Pathophysiology and Therapeutic Innovation » and directed by Pr Marc Humbert. She is co-founder and Head of Science of ALSYMO. This company promotes the results of her research after maturation at SATT Paris Saclay, the local technology transfer acceleration office.

ALSYMO is developing an innovative therapeutic target and a first-in-class drug candidate protected by 3 families of patents issued worldwide for a disease-modifying treatment for Pulmonary Arterial Hypertension, a rare respiratory disease. This breakthrough innovation targets peripheral pulmonary vascular NMDA receptors, major players in vascular remodeling leading to PAH. The ambition is to bring this drug candidate to proof of human efficacy within 5 years.

She holds a Ph.D. in Immunology, obtained in 1988, and a Habilitation to Direct Research (HDR), acquired in 1998. She is a 2020 graduate from the « Life Science Leadership School, » an original MBA-like program dedicated to life sciences and healthcare entrepreneurship. She began her career at CNRS in 1990, working on autoimmunity, before joining Inserm in 2010, where she coordinates multidisciplinary diagnostic and therapeutic innovation projects to improve PAH. Thanks to her experience in innovation, she is a member of the Inserm Scientific Committee of Specialists CSS3 « Physiology and pathophysiology of major systems », the Scientific and Strategic Steering Committee COSS Carnot AP-HP (Assitance Publique-Hopitaux de Paris), the National Research Agency (ANR) LabCom Committee (Joint Labs for research involving private-public collaborations), the ANR CE17 « Translational Research on Health » Committee, and was recently appointed an alternate member of the Board of Directors of SATT Paris Saclay.

She is a member of international learned societies such as the ERS, the ATS, and the PVRI (Pulmonary Vascular Research Institute). As a member of the French Society for Immunology (SFI) since 1990 (board member 2006-2011 and general secretary 2012-2014), she has worked to promote equality for women in immunology and science. She represents the University Paris-Saclay on the Paris-Boston Women’s Forum, a network of universities for gender equality, an official initiative launched by the French Presidency of the G7. She is a Women in Sciences association member and participates in the Paris Saclay University Women in Sciences mentoring program dedicated to women PhD candidates.

Head of the scientific team and R&D for Cynbiose since 2018, I manage a team of 5 preclinical study directors. PhD in Neuroscience, I spent 10 years in academic research in France and Japan, before joining Cynbiose. Using my knowledge of the primate model, GLP and NC3R guidelines, I ensure that the protocol we implement for our sponsors have the best added value possible. Among others, I was instrumental in developing our NHP model of SARS-CoV-2 infection.

Dr. Samuel Constant is co-founder and Chief Executive Officer of Epithelix ( a Swiss biotech company specialized in tissue engineering.

Epithelix is a leader for in vitro assessment of drug efficacy and toxicity on human respiratory tract. Epithelix has developed unique 3D in vitro human airway tissues and testing services for studying airway pathologies like Asthma, Cystic Fibrosis and Chronic Obstructive Pulmonary Diseases, Bacterial and Viral infections. Samuel is in charge of global management and strategy the company.

Since 2006, Dr. Samuel Constant and his team have won 18 prizes for their scientific achievements, technological innovation, and business development.

Docteur en écologie microbienne, je me suis spécialisé dans l’étude des microorganismes dans l’environnement avec des applications dans les domaines des biostimulants, biofertilisants et Biocontrôle. J’ai 10 ans d’expérience dans les métiers de la recherche et développement, avec 5 ans dans la recherche académique et 5 ans dans la R&D dans le secteur privé. Je me suis ainsi spécialisé dans le montage de projets de R&D reposant sur un partenariat public/privé. Engagé dans une nouvelle aventure en temps qu’associé de IAGE depuis début 2021, où j’assure la fonction de Directeur Scientifique, je m’intéresse plus spécialement à valoriser les résultats de la recherche académique sous la forme de méthodes de diagnostic innovantes et précoce.

Evelyne Géhin serves as a full professor at the Université Paris-Est, in Créteil, France. She has a Ph.D in Physics from the Université Paris 6 (Pierre et Marie Curie), France. Prof. Géhin is director of the Center for Studies and Research in Environment and Systems at Université Paris-Est Créteil were she leads the research group “Source and Transfers of Airborne Contaminants” from 2002 to 2015. She is the executive President of the French Association for Aerosols Research (ASFERA), a board member of European Aerosol Assembly, and a board member of International Aerosol Research Assembly (IARA). Since 2020 she’s a Member of the French High Council for Public Health (Haut Conseil en Santé Public) within the CSRE (Commission specialized in environmental risks).

Her research interests are to understand the determinants of airborne contamination (aerosols and gas) in indoor environment. The research focuses on the development of experimental devices, models and statistical methods to enable identification and characterization of sources and transport of air contaminants in buildings. She has extensive experience in national research projects and PhD studies. Evelyne has been involved in different projects (networks or collaborative actions), and she is coordinating the  “Indoor Air Quality” program for the master “Science and Environmental Engineering” at Université Paris Cité and Université Paris-Est Créteil.

Thomas Guillard est professeur de bactériologie à la Faculté de médecine de Reims et praticien hospitalier au CHU de Reims (France). Après des études de pharmacie, un internat en biologie médicale et un doctorat en infectiologie, il a effectué son postdoctorat à Harvard Medical School. Il est lauréat de l’Académie Nationale de Médecine et l’Académie Nationale de Pharmacie pour son travail de Doctorat. Il est actuellement chef du service de bactériologie-virologie-hygiène hospitalière du CHU de Reims et dirige l’axe  » bactériologie  » au sein de l’unité Inserm UMR-S 1250 P3Cell. Ses recherches portent sur la réponse antibactérienne oxydative et l’homéostasie du phosphate de l’épithélium respiratoire dans le contexte des infections bactériennes dans les maladies respiratoires chroniques. Il appartient au comité éditorial de Plos Pathogens de la section bacille gram négatif. Il a publié près d’une centaine d’articles scientifiques évalués par les pairs.

Geneviève Héry-Arnaud est professeure de bactériologie à la Faculté de médecine et praticien hospitalier au CHU de Brest (France). Après des études de pharmacie, un stage en biologie médicale et un doctorat en sciences de la vie et de la santé, elle a effectué une année postdoctorale à l’Institut Micalis (INRAE). Elle dirige actuellement le groupe  » Microbiota  » au sein de l’unité INSERM UMR1078. Ses recherches portent sur l’écosystème respiratoire (axe intestin-poumon, biomarqueurs, résistome) dans le contexte des infections bactériennes et virales dans les maladies respiratoires chroniques. Elle a créé le Centre d’Analyse du Microbiote de Brest, une plateforme dédiée à la mise en œuvre de l’analyse du microbiome dans les essais de recherche clinique. Elle a publié près d’une centaine d’articles scientifiques évalués par les pairs. Elle dirige actuellement deux études cliniques prospectives nationales portant sur les microbiomes respiratoire et intestinal. Elle vient de publier un livre intitulé « Ces microbes qui nous veulent du bien » (Ed. HumenSciences).

Jan’s main fields of interest are cell and molecular biology, oncology and toxicology. Throughout his career he has been involved in many projects aimed at development of diagnostic and testing methods as well as on understanding the molecular mechanisms involved in development of cancer. Currently he is member of SETOX and ESTIV. He coauthored 12 publications (240 cited references); 2 book chapters; and is a frequent speaker at international meetings and conferences.

Specialties: cell culture, 3D culture optimization, intestinal toxicity/metabolism assays, development and implementation of molecular biology tests for hereditary and sporadic cancers, transcriptional regulation, chromatin remodeling.

Dr. Hanan Osman-Ponchet, a leader in the field of in vitro testing, leverages her extensive experience to drive innovation at PKDERM. A seasoned scientist with over 20 years in drug development at Sanofi and Galderma, Dr. Osman-Ponchet holds a PhD in Biochemistry, Cellular and Molecular Biology. Combining this expertise with a Global Executive-MBA, she founded PKDERM, a French biotech company pioneering in vitro solutions for pharmaceutical and cosmetic product evaluation. A prolific author with over 30 publications and patents and a sought-after speaker, Dr. Osman-Ponchet’s dedication to scientific advancement and entrepreneurial spirit position PKDERM at the forefront of in vitro testing solutions. For further information, please visit her LinkedIn profile or personal website.